The number of women prescribed hormone replacement therapy (HRT) for menopause symptoms has more than doubled in the past five years, reaching a record high in 2025/26. According to data from the NHS Business Services Authority, around two million women over the age of 40 received HRT last year, up from approximately 800,000 in 2020/21.
Women aged 50 to 54 remain the most likely to be prescribed HRT, although the most significant increase in prescriptions has occurred among those aged 40 to 49. Health officials attribute the rise to growing demand for menopause care and heightened awareness of available treatment options.
HRT is used to alleviate menopause symptoms by supplementing declining levels of the hormones oestrogen and progesterone. Despite the overall increase in usage, the data indicates that women residing in more deprived areas are less likely to receive HRT, suggesting disparities in access to treatment.
Dr. Sue Mann, the national clinical director for women’s health at NHS England, noted that increased awareness of menopause has played a crucial role in encouraging dialogue around women’s health issues and facilitating greater access to support and care options.
The trend highlights a significant shift in healthcare engagement related to menopause, reflecting broader public and clinical recognition of its impact on women’s health and well-being.